Analytical method development and validation of rivaroxaban in bulk and pharmaceutical dosage form by using RP-HPLC

  • Awatade P
  • Veer V
  • Kasabe A
  • et al.
N/ACitations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

A simple, specific, accurate, and precise reverse phase high performance liquid chromatography (RP-HPLC0 method was developed and validated to analyse Rivaroxaban bulk dosage form. Using  Sun Q C18  HPLC column separation was carried out. This was maintained at ambient temperature. During separation mobile phase consist of Acetonitrile : Buffer(sodium acetate buffer) 80:20 was delivered at a flow rate of 1mL/min. Using UV detector analysis was carried out at the wavelength 249 nm. RP-HPLC method was validated by using various parameter like system suitability, linearity, specificity, precision, limit of detection, limit of quantification and robustness. The RP-HPLC method was found to be linear over the concentration range from 5-30 µg/mL (r2 =0.994). Retention time for bulk rivaroxaban was found to be 3.69 min. LOQ of method was 1.331 µg/mL and LOD 0.439 µg/mL. Thus the developed RP-HPLC method was found to be robust which can be applied for the regular analysis of Rivaroxaban in the bulk as well as pharmaceutical dosage form

Cite

CITATION STYLE

APA

Awatade, P. R., Veer, V. S., Kasabe, A. J., & Dhepe, S. D. (2022). Analytical method development and validation of rivaroxaban in bulk and pharmaceutical dosage form by using RP-HPLC. International Journal of Health Sciences, 14688–14702. https://doi.org/10.53730/ijhs.v6ns2.8879

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free